SCHEMBL31023665

SCHEMBL31023665

CCOC(=O)N1CCC(=C(c2ccc3c(c2)COCO3)c2ccc3c(c2)COCO3)CC1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 9/20 0.43
▸ HPGD P15428 3/20 0.43
▸ KDM4E B2RXH2 2/20 0.43
▸ MGLL Q99685 1/20 0.42
▸ KMT2A Q03164 2/20 0.42
▸ CYP2C19 P33261 2/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ ALOX15 P16050 1/20 0.41
▸ CHRM2 P08172 1/20 0.40
▸ HSD17B10 Q99714 2/20 0.39
▸ MAPT P10636 2/20 0.39
▸ POLB P06746 3/20 0.39
▸ NPSR1 Q6W5P4 1/20 0.39
▸ LMNA P02545 2/20 0.39
▸ GAA P10253 2/20 0.39
▸ SMN1; SMN2 Q16637 1/20 0.39
▸ MEN1 O00255 1/20 0.38
▸ RXFP1 Q9HBX9 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31023851 0.96 ALDH1A1 (0.41) ALDH1A1HPGDKDM4EMGLLKMT2A
SCHEMBL31023895 0.94 ALDH1A1 (0.42) ALDH1A1HPGDKDM4EMGLLKMT2A
SCHEMBL31023947 0.80 OPRM1 (0.41) ALDH1A1HPGDCHRM2MAPTPOLB
SCHEMBL31023708 0.75 MGLL (0.48) ALDH1A1HPGDKDM4EMGLLKMT2A
SCHEMBL31023918 0.72 OPRD1 (0.36) ALDH1A1MGLL
SCHEMBL31023705 0.72 MGLL (0.46) ALDH1A1HPGDKDM4EMGLLKMT2A
SCHEMBL31023858 0.72 MGLL (0.50) ALDH1A1HPGDMGLLCYP2C19CYP2C9
SCHEMBL4693977 0.72 TSHR (0.57) ALDH1A1HPGDKDM4EKMT2ACYP2C19
SCHEMBL31023711 0.72 SCD5 (0.37) HPGDMAPTPOLB
SCHEMBL9047536 0.71 ALDH1A1 (0.58) ALDH1A1KDM4EKMT2ACYP2C19CHRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4665718-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF Apogee Pharmaceuticals, Inc. (CA) 2025-12-24 — — EP disclosed
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof APOGEE PHARMACEUTICALS, INC. (CA) 2025-08-05 — — US disclosed
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-09-05 — — US disclosed
WO-2024168426-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF APOGEE PHARMACEUTICALS, INC. (CA) 2024-08-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12378231-B2 Small molecules as monoacylglycerol lipase (MAGL) inhibitors, compositions and use thereof MGLL, PNLIP, LPL ALDH1A1 530/4885HPGD 1304/4885KDM4E 2756/4885
US-20240294514-A1 SMALL MOLECULES AS MONOACYLGLYCEROL LIPASE (MAGL) INHIBITORS, COMPOSITIONS AND USE THEREOF MGLL, PNLIP, LPL ALDH1A1 530/4885HPGD 1304/4885KDM4E 2756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback